| Literature DB >> 31788093 |
Xiaoli Ji1, Shisheng Zhou2, Peng Yang3, Faqin Liu4, Yan Li4, Hong Li5.
Abstract
Ultrasound (US) combined with magnetic resonance imaging (MRI) in the diagnosis of primary hepatocellular carcinoma (PHCC) and recurrent hepatocellular carcinoma (RHCC) were compared. The clinical data of 329 patients with hepatocellular carcinoma (HCC) admitted to Qingdao Women and Children's Hospital from June 2015 to December 2017 were collected. One hundred and sixty patients with PHCC were regarded as the PHCC group, and the other 169 patients with RHCC were regarded as the RHCC group. US and MRI were used in the imaging diagnosis of both groups and the results of US combined with MRI, US, and MRI alone were compared. The lesion size in the PHCC group was significantly higher than that in the RHCC group (P<0.05). The MRI fast-in and fast-out rates of the two groups were significantly higher than those of the other three methods (P<0.05). The coincidence rate of MRI in the two groups was higher than that of computed tomography (CT), US, and US combined with MRI (P<0.05). The coincidence rates of CT, US, MRI, and US combined with MRI in PHCC group were significantly higher than those in RHCC group. In PHCC group, MRI was superior to the other methods in the detection of micro HCC (P<0.05). In RHCC group, MRI was significantly better than US in the detection of micro HCC (P<0.05). The sensitivity, specificity, positive predictive value and negative predictive value of MRI were significantly better than the other three methods (P<0.05). MRI alone has the best diagnostic efficacy for micro HCC-type lesions. The diagnostic efficacy of MRI, US, CT, and US combined with MRI in PHCC was better than those in RHCC. In addition to imaging examination, the diagnosis of RHCC should be combined with other indicators for comprehensive diagnosis. Copyright: © Ji et al.Entities:
Keywords: diagnostic value; magnetic resonance imaging; primary hepatocellular carcinoma; recurrent hepatocellular carcinoma; ultrasound
Year: 2019 PMID: 31788093 PMCID: PMC6864961 DOI: 10.3892/ol.2019.10945
Source DB: PubMed Journal: Oncol Lett ISSN: 1792-1074 Impact factor: 2.967
HCC classification (according to lesion size).
| Types | Diameter of lesions (cm) |
|---|---|
| Micro HCC | ≤2 |
| Small HCC | 2-5 |
| Large HCC | 5-10 |
| Huge HCC | >10 |
HCC, hepatocellular carcinoma.
General clinical data of the two groups of patients.
| Factors | PHCC group (n=160) | RHCC group (n=169) | χ2/t value | P-value |
|---|---|---|---|---|
| Age (years) | 53.54±21.45 | 55.76±23.54 | 0.895 | 0.372 |
| Sex [n (%)] | 3.011 | 0.083 | ||
| Male | 120 (75.00) | 112 (66.27) | ||
| Female | 40 (25.00) | 57 (33.73) | ||
| HCC type [n (%)] | 0.966 | 0.326 | ||
| Bureau | 88 (55.00) | 102 (60.36) | ||
| Nodular | 72 (45.00) | 67 (39.64) | ||
| Lesion location [n (%)] | 0.043 | 0.979 | ||
| Left liver | 34 (21.25) | 37 (21.89) | ||
| Right liver | 108 (67.50) | 114 (67.46) | ||
| Left and right liver | 18 (11.25) | 18 (10.65) | ||
| Lesion size (cm) | 3.98±1.67 | 3.23±1.32 | 4.503 | <0.001 |
| Total no. of lesions | 1.22±1.01 | 1.06±0.96 | 1.471 | 0.143 |
| Serum AFP [n (%)] | 0.275 | 0.600 | ||
| ≥400 ng/ml | 126 (78.75) | 137 (81.07) | ||
| <400 ng/ml | 34 (21.25) | 32 (18.93) |
PHCC, primary hepatocellular carcinoma; RHCC, recurrent hepatocellular carcinoma; HCC, hepatocellular carcinoma; AFP, α-fetoprotein.
Image performance after angiography in PHCC patients [n (%)].
| Methods | Fast in and fast out | Fast in and slow out |
|---|---|---|
| CT | 110 (68.75)[ | 50 (31.25)[ |
| US | 121 (75.63)[ | 39 (24.37)[ |
| MRI | 149 (93.13) | 11 (6.88) |
| US combined with MRI | 115 (71.88)[ | 45 (28.12)[ |
P<0.05, compared with MRI in the same group. PHCC, primary hepatocellular carcinoma; CT, computed tomography; US, ultrasound; MRI, magnetic resonance imaging.
Image performance after angiography in RHCC patients [n (%)].
| Methods | Fast in and fast out | Fast in and slow out |
|---|---|---|
| CT | 88 (52.07)[ | 81 (47.93)[ |
| US | 98 (57.99)[ | 71 (42.01)[ |
| MRI | 121 (71.60) | 48 (28.40) |
| US combined with MRI | 78 (46.15)[ | 91 (53.85)[ |
P<0.05, compared with MRI in the same group. RHCC, recurrent hepatocellular carcinoma; CT, computed tomography; US, ultrasound; MRI, magnetic resonance imaging.
Comparison of coincidence rate between the two groups [n (%)].
| Methods | RHCC group (n=169) | PHCC group (n=160) | χ2 value | P-value |
|---|---|---|---|---|
| CT | 88 (52.07)[ | 106 (66.25)[ | 6.830 | 0.009 |
| US | 98 (57.99)[ | 121 (75.63)[ | 11.49 | <0.001 |
| MRI | 121 (71.60) | 149 (93.13) | 25.88 | <0.001 |
| US combined with MRI | 78 (46.15)[ | 115 (71.88)[ | 22.42 | <0.001 |
P<0.05, compared with MRI in the same group. RHCC, recurrent hepatocellular carcinoma; PHCC, primary hepatocellular carcinoma; CT, computed tomography; US, ultrasound; MRI, magnetic resonance imaging.
Comparison of coincidence rate of CT, US and MRI in the group of patients with PHCC [n (%)].
| Types | No. of lesions | CT | US | MRI | US combined with MRI |
|---|---|---|---|---|---|
| Micro HCC | 100 | 36 (36)[ | 40 (40)[ | 54 (54) | 43 (43)[ |
| Small HCC | 53 | 22 (41.51) | 26 (49.06) | 29 (54.72) | 35 (66.04) |
| Large HCC | 15 | 15 (100) | 15 (100) | 15 (100) | 15 (100) |
| Huge HCC | 2 | 2 (100) | 2 (100) | 2 (100) | 2 (100) |
P<0.05, compared with MRI in the same group. PHCC, primary hepatocellular carcinoma; CT, computed tomography; US, ultrasound; MRI, magnetic resonance imaging; HCC, hepatocellular carcinoma.
Comparison of coincidence rate of CT, US and MRI in the group of patients with RHCC [n (%)].
| Types | No. of lesions | CT | US | MRI | US combined with MRI |
|---|---|---|---|---|---|
| Micro HCC | 150 | 53 (35.33)[ | 55 (36.67)[ | 78 (52.00) | 65 (43.33) |
| Small HCC | 38 | 17 (44.74) | 18 (47.37) | 19 (50.00) | 26 (68.42) |
| Large HCC | 7 | 7 (100.00) | 7 (100.00) | 7 (100.00) | 7 (100.00) |
| Huge HCC | 0 | 0 | 0 | 0 | 0 |
P<0.05, compared with MRI in the same group. RHCC, recurrent hepatocellular carcinoma; CT, computed tomography; US, ultrasound; MRI, magnetic resonance imaging; HCC, hepatocellular carcinoma.
Comparison of detection rates of CT, US and MRI in the two groups [n (%)].
| Variables | CT | US | MRI | US combined with MRI |
|---|---|---|---|---|
| True positive [n (%)] | 75 (22.80) | 77 (23.40) | 100 (30.40) | 79 (24.01) |
| False positive [n (%)] | 99 (30.09) | 96 (29.18) | 71 (21.58) | 93 (28.27) |
| True negative [n (%)] | 70 (21.28) | 73 (22.19) | 98 (29.79) | 76 (23.10) |
| False negative [n (%)] | 85 (25.83) | 83 (25.23) | 60 (18.24) | 81 (24.62) |
| Sensitivity (%) | 46.88[ | 48.13[ | 62.50 | 49.38[ |
| Specificity (%) | 41.42[ | 43.20[ | 57.99 | 44.97[ |
| Positive predictive value (%) | 43.10[ | 44.51[ | 58.48 | 45.93[ |
| Negative predictive value (%) | 45.16[ | 46.79[ | 62.03 | 48.40[ |
P<0.05, compared with MRI in the same group. CT, computed tomography; US, ultrasound; MRI, magnetic resonance imaging.